RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Eli Lilly and Co Stock

Eli Lilly and Co P/S 2024

Eli Lilly and Co P/S

16.07

Ticker

LLY

ISIN

US5324571083

WKN

858560

As of Oct 19, 2024, Eli Lilly and Co's P/S ratio stood at 16.07, a 39.13% change from the 11.55 P/S ratio recorded in the previous year.

The Eli Lilly and Co P/S history

Eli Lilly and Co Aktienanalyse

What does Eli Lilly and Co do?

Eli Lilly and Co. is a global biopharmaceutical company headquartered in Indianapolis, Indiana, USA. The company was founded in 1876 by Colonel Eli Lilly with the aim of manufacturing pharmaceutical products of the highest quality. Eli Lilly began his career in the pharmacy industry and opened his own pharmacy in Indianapolis in 1876. He quickly developed his own medications and eventually established Eli Lilly and Company in 1901. Over the years, the company has continued to evolve and expand its business into numerous areas. Eli Lilly is focused on biopharmaceutical research and development and operates in areas such as oncology, diabetes, neurology, and others. The company's main goal is to develop drugs that can change and improve lives. Eli Lilly invests a high percentage of its revenue into research and development every year. The company has several strategic business units, including human pharmaceuticals, animal pharmaceuticals, and oncology research. Eli Lilly is divided into five main divisions: diabetes, oncology, immunology, neurology, and animal health. The diabetes division focuses on manufacturing insulin products and glucose sensors for the treatment of type 1 and type 2 diabetes, as well as blood glucose meters and other diabetes products. The oncology division focuses on researching and developing drugs to treat cancer. The company currently has several compounds in clinical trials, including a new preparation for the treatment of breast cancer. The immunology division focuses on products for the treatment of autoimmune and inflammatory diseases, such as psoriasis. The neurology division focuses on researching and developing drugs to treat diseases of the nervous system, such as Alzheimer's. The animal health division focuses on animal health products, such as drugs for the treatment of infections in livestock and pets. Eli Lilly is primarily known for its insulin products and treatments in the field of oncology. Some of the company's most well-known products include Humalog, Forteo, Alimta, and Cymbalta. The effectiveness and compliance of the products are monitored by a quality and safety system to ensure that patients receive the highest quality medications. In conclusion, Eli Lilly and Co. is a company with a long history and a unique business model. The company specializes in developing high-quality pharmaceutical products and has continued to evolve since its founding. Eli Lilly has become a leader in various areas such as diabetes, oncology, immunology, neurology, and animal health. They are known for their insulin products and treatments in the field of oncology. The company remains committed to expanding its reach and presence globally and continues to develop innovative products that can improve and change people's lives. Eli Lilly and Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Eli Lilly and Co's P/S Ratio

Eli Lilly and Co's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Eli Lilly and Co's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Eli Lilly and Co's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Eli Lilly and Co’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Eli Lilly and Co stock

What is the price-to-earnings ratio of Eli Lilly and Co?

The price-earnings ratio of Eli Lilly and Co is currently 16.07.

How has the price-earnings ratio of Eli Lilly and Co changed compared to last year?

The price-to-earnings ratio of Eli Lilly and Co has increased by 39.13% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Eli Lilly and Co high compared to other companies?

Yes, the price-to-earnings ratio of Eli Lilly and Co is high compared to other companies.

How does an increase in the price-earnings ratio of Eli Lilly and Co affect the company?

An increase in the price-earnings ratio of Eli Lilly and Co would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Eli Lilly and Co affect the company?

A decrease in the price-earnings ratio of Eli Lilly and Co would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Eli Lilly and Co?

Some factors that influence the price-earnings ratio of Eli Lilly and Co are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Eli Lilly and Co pay?

Over the past 12 months, Eli Lilly and Co paid a dividend of 4.52 USD . This corresponds to a dividend yield of about 0.49 %. For the coming 12 months, Eli Lilly and Co is expected to pay a dividend of 5.73 USD.

What is the dividend yield of Eli Lilly and Co?

The current dividend yield of Eli Lilly and Co is 0.49 %.

When does Eli Lilly and Co pay dividends?

Eli Lilly and Co pays a quarterly dividend. This is distributed in the months of December, March, June, September.

How secure is the dividend of Eli Lilly and Co?

Eli Lilly and Co paid dividends every year for the past 26 years.

What is the dividend of Eli Lilly and Co?

For the upcoming 12 months, dividends amounting to 5.73 USD are expected. This corresponds to a dividend yield of 0.62 %.

In which sector is Eli Lilly and Co located?

Eli Lilly and Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eli Lilly and Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eli Lilly and Co from 9/10/2024 amounting to 1.3 USD, you needed to have the stock in your portfolio before the ex-date on 8/15/2024.

When did Eli Lilly and Co pay the last dividend?

The last dividend was paid out on 9/10/2024.

What was the dividend of Eli Lilly and Co in the year 2023?

In the year 2023, Eli Lilly and Co distributed 3.92 USD as dividends.

In which currency does Eli Lilly and Co pay out the dividend?

The dividends of Eli Lilly and Co are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Eli Lilly and Co stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank

Andere Kennzahlen von Eli Lilly and Co

Our stock analysis for Eli Lilly and Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eli Lilly and Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.